Rituximab therapy for Severe and Persistent Lichenoid drug-reaction

  • Kamel El-Reshaid Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait
  • Shaima Al-Bader Asad Al-Bahar dermatology Center, Kuwait


We report on a patient with severe and fixed lichenoid drug-reaction.  She did not respond to 2 months treatment with high-dose corticosteroids.  Hence, Rituximab was given.  One month later, her lesions improved and remained stable for 14 months of follow up.   

Keywords: fixed drug reaction, Prednesone, Rituximab.


Download data is not yet available.

Author Biographies

Kamel El-Reshaid, Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait

Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait

Shaima Al-Bader, Asad Al-Bahar dermatology Center, Kuwait

Asad Al-Bahar dermatology Center, Kuwait


1- Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129:1088.
2- Sehgal VN, Srivastava G, Sharma S, Sehgal S, Verma P. Lichenoid tissue reaction/interface dermatitis: Recognition, classification, etiology, and clinicopathological overtones. Indian Journal of Dermatology, Venereology and Leprology 2011; 77:418-430.
3- Ellgehausen P, Elsner P, Berger G. Drug induced lichen planus. Clin Dermatol 1998; 16:325-332.
4- Sehgal VN, Srivastava G. Fixed Drug Eruption (FDE): Changing scenario of incriminating drugs. Int J Dermatol 2006; 45:897-908.
5- Bayer HealthCare Pharmaceuticals Inc. Cipro (ciprofloxacin hydrochloride) tablets and Cipro (ciprofloxacin) for oral suspension prescribing information. Whippany, NJ; 2016 Jul.
6- Shai A, Halevy S. Lichen Planus and lichen planus-like eruptions: Pathogenesis and associated diseases. Int J Dermatol 1992; 31:379-84.
7- Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminitive criteria between lichenoid drug eruption and idiopathic lichen planus: Retrospective study on selected samples. Dermatoloica 1989; 179:10-13.
8- Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev2005; 4:236-241.
9- Mizukawa Y, Shiohara T. Fixed drug eruption: A prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9:71-77.
10- Crowson AN, Magro CM, Mihm MC Jr. Interface Dermatitis. Arch Pathol Lab Med 2008; 132:652-666.
11- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
12- Johnson P, Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30:(sup.2):2-8.
13- Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is a B cell dependent. J Immunol 2001; 167:4710-4718.
14- Muhammad K, Roll P, Einsele H, Dorner T, Tony HP. Delayed acquisition of somatic hypermutations in repopulated IgD+CD27+memory B cell receptors after rituximab treatment. Arthritis Rheum 2009; 60:2284-2293
199 Views | 204 Downloads
How to Cite
El-Reshaid K, Al-Bader S. Rituximab therapy for Severe and Persistent Lichenoid drug-reaction. JDDT [Internet]. 15Jun.2019 [cited 20May2022];9(3-s):751-3. Available from: http://jddtonline.info/index.php/jddt/article/view/2873

Most read articles by the same author(s)